Exploring the potential role of gut microbiota in improving outcomes of chronic myeloid leukemia patients
Progetto Philadelphia positive (Ph+) Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm that originates from a pluripotent hematopoietic cell. CML treatment is based on targeted drugs called tyrosine-kinase inhibitors (TKIs) which have dramatically improved long-term survival rates